Structure Therapeutics Inc. 8-K

What Happened

• Structure Therapeutics Inc. held its 2026 Annual General Meeting of Shareholders on June 17, 2026 and filed the voting results on Form 8-K. As of the April 20, 2026 record date, 213,213,565 ordinary shares were outstanding and entitled to vote.
• Three directors — Ted W. Love, M.D., Raymond Stevens, Ph.D., and Daniel G. Welch — were elected as Class III directors to serve until the 2029 Annual Meeting. Shareholders also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the advisory vote on executive compensation (say‑on‑pay).

Key Details

• Director election votes:
  • Ted W. Love, M.D.: 164,241,780 For; 533,358 Against; 172,641 Abstentions.
  • Raymond Stevens, Ph.D.: 164,373,741 For; 400,929 Against; 173,109 Abstentions.
  • Daniel G. Welch: 161,336,058 For; 3,429,342 Against; 182,379 Abstentions.
• Auditor ratification: Ernst & Young LLP ratified with 164,767,215 For; 20,784 Against; 159,780 Abstentions.
• Advisory vote on executive compensation: approved with 158,547,441 For; 6,187,647 Against; 212,691 Abstentions.
• There were no broker non‑votes reported for these matters.

Why It Matters

• Board continuity: Election of the three Class III directors secures leadership and oversight until 2029, which can affect strategic consistency and governance.
• Financial reporting: Ratification of Ernst & Young LLP confirms continuity of the company’s independent auditor for 2026, relevant to the reliability and timing of financial statements.
• Shareholder sentiment on pay: The approved say‑on‑pay vote signals majority shareholder support for the company’s disclosed executive compensation, an important governance metric for investors.